ArticleBMJ oncology2024

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis.

Hui-Chuan Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.